Truist Securities Reiterates Buy on PTC Therapeutics, Maintains $65 Price Target
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Barry Jonas has reiterated a 'Buy' rating on PTC Therapeutics (NASDAQ:PTCT) and maintained a price target of $65.
August 16, 2023 | 3:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PTC Therapeutics has received a reiterated 'Buy' rating from Truist Securities, with a maintained price target of $65.
The reiterated 'Buy' rating and maintained price target by Truist Securities indicates a positive outlook for PTC Therapeutics. This could potentially lead to increased investor confidence and a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100